Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Enanta Pharma Q4 EPS $(0.87) Beats $(1.03) Estimate, Sales $15.125M Miss $15.956M Estimate

Author: Benzinga Newsdesk | November 17, 2025 04:02pm
Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of $(1.03) by 15.29 percent. This is a 36.03 percent increase over losses of $(1.36) per share from the same period last year. The company reported quarterly sales of $15.125 million which missed the analyst consensus estimate of $15.956 million by 5.21 percent. This is a 3.55 percent increase over sales of $14.607 million the same period last year.

Posted In: ENTA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist